Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN LIU

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1184788432
CMS profile
190501
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$177,268.42

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN LIU

NPI 1184788432 · CMS profile ID 190501

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN LIU, NPI 1184788432, CMS profile ID 190501. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEPHEN LIU, NPI 1184788432, CMS profile ID 190501. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEPHEN LIU, NPI 1184788432, CMS profile ID 190501, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $177,268.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–139 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $158.6203/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695415061 CMS
Merck Sharp & Dohme Corporation $23.6003/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695415063 CMS
Merck Sharp & Dohme Corporation $245.2403/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695415065 CMS
Merck Sharp & Dohme Corporation $256.7703/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695415067 CMS
Merck Sharp & Dohme Corporation $9,217.0903/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695415229 CMS
Genentech USA, Inc. $3,640.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681338801 CMS
AstraZeneca Pharmaceuticals LP $2,775.0003/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685948763 CMS
AstraZeneca Pharmaceuticals LP $2,775.0003/10/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685806419 CMS
AstraZeneca UK Limited $7,000.0003/06/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685798215 CMS
Takeda Pharmaceuticals U.S.A., Inc. $8,400.0003/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697379591 CMS
Takeda Pharmaceuticals U.S.A., Inc. $502.7903/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697379799 CMS
Takeda Pharmaceuticals U.S.A., Inc. $179.9003/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697411695 CMS
Celgene Corporation $600.0002/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672720527 CMS
Genentech USA, Inc. $198.8702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681149035 CMS
Genentech USA, Inc. $200.0002/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681248695 CMS
Genentech USA, Inc. $447.8702/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681264653 CMS
Genentech USA, Inc. $4,400.0002/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681296235 CMS
AstraZeneca UK Limited $139.8302/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685060665 CMS
AstraZeneca Pharmaceuticals LP $69.8302/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685462601 CMS
AstraZeneca UK Limited $32.9702/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685130485 CMS
AstraZeneca UK Limited $14.7802/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685373087 CMS
AstraZeneca UK Limited $14.7802/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685540455 CMS
AstraZeneca UK Limited $10,878.3302/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685060279 CMS
AstraZeneca UK Limited $6.5502/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685136385 CMS
AstraZeneca UK Limited $47.7502/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685338655 CMS
AstraZeneca UK Limited $443.3502/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685890819 CMS
AstraZeneca UK Limited $20.4602/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685972397 CMS
AstraZeneca UK Limited $233.0402/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685981731 CMS
AstraZeneca Pharmaceuticals LP $376.9501/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685921505 CMS
AstraZeneca Pharmaceuticals LP $40.0001/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685925475 CMS
Merck Sharp & Dohme Corporation $8,500.0001/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372269 CMS
AstraZeneca Pharmaceuticals LP $3,720.0001/07/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685124051 CMS
Merck Sharp & Dohme Corporation $19.0001/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372245 CMS
Merck Sharp & Dohme Corporation $23.0001/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372249 CMS
Merck Sharp & Dohme Corporation $19.0001/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372241 CMS
Merck Sharp & Dohme Corporation $345.0001/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372253 CMS
Merck Sharp & Dohme Corporation $5,339.0001/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372261 CMS
Merck Sharp & Dohme Corporation $540.0001/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372265 CMS
Merck Sharp & Dohme Corporation $44.0001/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695372257 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $177,268.42 139
PY2020 $83,558.04 43
PY2021 $79,830.16 36
PY2022 $65,048.71 53
PY2023 $110,539.99 90
PY2024 $101,943.83 78
PY2025 $131,599.42 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,784.06 6
PY2025 Principal investigator $891,018.79 178
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $1,653,888.85 126
PY2023 Principal investigator $1,104,134.85 45
PY2022 Recipient $1,967.66 1
PY2022 Principal investigator $793,468.72 28
PY2021 Recipient $4,288.84 6
PY2021 Principal investigator $978,939.81 53
PY2020 Recipient $12,864.69 21
PY2020 Principal investigator $886,024.56 67
PY2019 Recipient $3,323.20 1
PY2019 Principal investigator $936,390.66 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

184 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202532538
Principal investigator 1 Merck Sharp & Dohme LLC $6,010.67 12/31/2025 Non-covered Recipient Entity
Georgetown University
KEYMAKER-U01 Substudy 01A# A Phase 1,2, Umbrella Study With Rolling Arms of Investigational Agents, With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 1232924760
Principal investigator 1 Merck Sharp & Dohme LLC $48.62 12/31/2025 Non-covered Recipient Entity
Georgetown University
KEYMAKER U01Substudy 2# A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Na ve Patients with PD-L1 Positive Advanced Non-Small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 1232925223
Principal investigator 1 Merck Sharp & Dohme LLC $161,551.60 12/31/2025 Non-covered Recipient Entity
Georgetown University
KEYMAKER-U01 Master Study# A Phase 1,2, Umbrella Study with Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants with Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 1232928457
Principal investigator 1 Merck Sharp & Dohme LLC $15,450.74 12/31/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232939895
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610120
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610124
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610128
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610132
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610136
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610144
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610148
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610153
Principal investigator 1 Genentech, Inc. $16.50 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610157
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610161
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610164
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610169
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610174
Principal investigator 1 Genentech, Inc. $2,467.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610178
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610184
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610189
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610193
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610197
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610201
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610205
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610208
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610212
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610216
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610220
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610224
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610228
Principal investigator 1 Genentech, Inc. $1,634.80 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610233
Principal investigator 1 Genentech, Inc. $439.00 12/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610239
Principal investigator 1 Incyte Corporation $18,385.00 12/24/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474106
Principal investigator 1 ABBVIE INC. $365.30 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531384
Principal investigator 1 ABBVIE INC. $365.30 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531386
Principal investigator 1 ABBVIE INC. $2,347.80 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531410
Principal investigator 1 ABBVIE INC. $365.30 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531412
Principal investigator 1 ABBVIE INC. $344.50 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531414
Principal investigator 1 ABBVIE INC. $975.27 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531416
Principal investigator 1 ABBVIE INC. $1,006.94 12/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202531418
Recipient F. Hoffmann-La Roche AG $781.10 12/11/2025 Covered Recipient Physician 1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211539043
Recipient F. Hoffmann-La Roche AG $1,143.94 12/11/2025 Covered Recipient Physician 1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211539050
Principal investigator 1 Genentech, Inc. $650.00 12/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610116
Principal investigator 1 Genentech, Inc. $500.00 12/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610140
Principal investigator 1 ABBVIE INC. $4,463.00 11/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202525768
Principal investigator 1 ABBVIE INC. $1,543.00 11/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202525770
Principal investigator 1 ABBVIE INC. $1,543.00 11/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202525772
Recipient F. Hoffmann-La Roche AG $3,691.13 11/27/2025 Covered Recipient Physician 1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211539039
Principal investigator 1 Genentech, Inc. $1,014.00 11/20/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211610398
Principal investigator 1 Genentech, Inc. $5,925.00 11/05/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
An open label multicenter extension study No dispute reported 06/30/2026 1211610777
Principal investigator 1 Partner Therapeutics, Inc. $1,164.80 11/05/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516757
Principal investigator 1 ABBVIE INC. $200.00 10/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519657
Principal investigator 1 ABBVIE INC. $200.00 10/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519659
Principal investigator 1 ABBVIE INC. $1,300.00 10/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519661
Principal investigator 1 ABBVIE INC. $200.00 10/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519663
Principal investigator 1 ABBVIE INC. $200.00 10/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519665
Principal investigator 1 ABBVIE INC. $1,690.00 10/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202519667
Principal investigator 1 ABBVIE INC. $1,543.00 10/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202518557
Principal investigator 1 ABBVIE INC. $1,543.00 10/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202518559
Principal investigator 1 ABBVIE INC. $1,543.00 10/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202518563
Recipient Novartis Pharma AG $1,080.75 10/18/2025 Covered Recipient Physician CAAA601A42101 No dispute reported 06/30/2026 1248109605
Principal investigator 1 Incyte Corporation $37.53 10/08/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240537178
Principal investigator 1 Genentech, Inc. $3,387.80 10/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
An open label multicenter extension study No dispute reported 06/30/2026 1211610773
Principal investigator 1 ABBVIE INC. $1,543.00 09/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512588
Principal investigator 1 ABBVIE INC. $4,463.00 09/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512590
Principal investigator 1 ABBVIE INC. $1,543.00 09/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512592
Principal investigator 1 ABBVIE INC. $4,463.00 09/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512608
Principal investigator 1 ABBVIE INC. $1,543.00 09/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512626
Principal investigator 1 ABBVIE INC. $365.30 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512212
Principal investigator 1 ABBVIE INC. $365.30 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512214
Principal investigator 1 ABBVIE INC. $975.27 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512226
Principal investigator 1 ABBVIE INC. $1,006.94 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512228
Principal investigator 1 ABBVIE INC. $2,347.80 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512252
Principal investigator 1 ABBVIE INC. $365.30 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512254
Principal investigator 1 ABBVIE INC. $344.50 09/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202512256
Principal investigator 1 Genentech, Inc. $6,172.00 09/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610104
Principal investigator 1 Genentech, Inc. $18,516.00 09/23/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610099
Principal investigator 1 Genentech, Inc. $9,904.00 09/23/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610108
Principal investigator 1 Genentech, Inc. $6,890.00 09/23/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211610357
Principal investigator 1 Genentech, Inc. $2,400.00 09/23/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211610361
Principal investigator 1 Genentech, Inc. $2,322.00 09/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610095
Principal investigator 1 Genentech, Inc. $1,248.00 09/22/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610112
Recipient F. Hoffmann-La Roche AG $1,641.54 09/17/2025 Covered Recipient Physician 1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211539047
Principal investigator 1 Genentech, Inc. $16,500.00 09/17/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
Neoadjuvant NSCLC No dispute reported 06/30/2026 1211610393
Principal investigator 1 ABBVIE INC. $1,543.00 09/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506669
Principal investigator 1 ABBVIE INC. $1,543.00 09/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506671
Principal investigator 1 ABBVIE INC. $1,543.00 09/01/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202506689
Principal investigator 1 ABBVIE INC. $1,543.00 08/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202500930
Principal investigator 1 ABBVIE INC. $4,463.00 08/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202500932
Principal investigator 1 AstraZeneca Pharmaceuticals LP $54,159.58 07/30/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185545093
Principal investigator 1 ABBVIE INC. $3,250.00 07/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202497532
Principal investigator 1 ABBVIE INC. $200.00 07/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202497534
Principal investigator 1 ABBVIE INC. $200.00 07/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202497536
Principal investigator 1 ABBVIE INC. $2,347.80 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496916
Principal investigator 1 ABBVIE INC. $344.50 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496918
Principal investigator 1 ABBVIE INC. $365.30 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496920
Principal investigator 1 ABBVIE INC. $1,006.94 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496922
Principal investigator 1 ABBVIE INC. $365.30 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496924
Principal investigator 1 ABBVIE INC. $975.27 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496928
Principal investigator 1 ABBVIE INC. $365.30 07/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202496930
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610653
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610657
Principal investigator 1 Genentech, Inc. $2,467.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610662
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610665
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610671
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610676
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610680
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610684
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610689
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610693
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610696
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610701
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610705
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610709
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610714
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610718
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610722
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610726
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610730
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610734
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610738
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610742
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610746
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610748
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610753
Principal investigator 1 Genentech, Inc. $832.20 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610757
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610760
Principal investigator 1 Genentech, Inc. $439.00 07/03/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV
STARTRK 2 RXDX 101 02 No dispute reported 06/30/2026 1211610764
Principal investigator 1 ABBVIE INC. $4,463.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202492931
Principal investigator 1 ABBVIE INC. $1,543.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202493095
Principal investigator 1 ABBVIE INC. $1,543.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202493097
Principal investigator 1 ABBVIE INC. $4,463.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202493105
Principal investigator 1 ABBVIE INC. $1,543.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202493107
Principal investigator 1 ABBVIE INC. $4,463.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202493109
Principal investigator 1 ABBVIE INC. $1,543.00 06/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202493111
Principal investigator 1 Merck Sharp & Dohme LLC $16,365.00 06/23/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232937050
Principal investigator 1 Incyte Corporation $11,524.00 06/05/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474094
Principal investigator 1 Incyte Corporation $11,680.00 06/05/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474098
Principal investigator 1 Incyte Corporation $600.00 06/05/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474102
Principal investigator 1 ABBVIE INC. $12,990.03 06/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202487165
Principal investigator 1 ABBVIE INC. $1,033.50 06/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202487257
Principal investigator 1 ABBVIE INC. $1,095.90 06/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202487259
Principal investigator 1 ABBVIE INC. $1,095.90 06/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202487261
Principal investigator 1 ABBVIE INC. $1,095.90 06/02/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202487267
Principal investigator 1 ABBVIE INC. $1,200.00 05/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486403
Principal investigator 1 ABBVIE INC. $3,575.00 05/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486405
Principal investigator 1 ABBVIE INC. $1,543.00 05/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486407
Principal investigator 1 ABBVIE INC. $1,543.00 05/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202486409
Principal investigator 1 Incyte Corporation $800.00 05/28/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474086
Principal investigator 1 Incyte Corporation $12,668.00 05/22/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474090
Recipient Novartis Pharma AG $445.60 05/13/2025 Covered Recipient Physician CAAA601A42101 No dispute reported 06/30/2026 1248109607
Principal investigator 1 ABBVIE INC. $4,463.00 04/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202479707
Principal investigator 1 ABBVIE INC. $1,543.00 04/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202479711
Principal investigator 1 Incyte Corporation $11,791.00 04/17/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474083
Principal investigator 1 Hoffmann-La Roche Limited $16,432.00 04/04/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610091
Principal investigator 1 ABBVIE INC. $4,463.00 03/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466417
Principal investigator 1 ABBVIE INC. $1,543.00 03/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202466422
Principal investigator 1 Hoffmann-La Roche Limited $47,412.00 03/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610082
Principal investigator 1 Hoffmann-La Roche Limited $832.00 03/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610066
Principal investigator 1 Hoffmann-La Roche Limited $16,525.08 03/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610078
Principal investigator 1 Hoffmann-La Roche Limited $20,280.78 03/21/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610086
Principal investigator 1 ABBVIE INC. $1,543.00 03/12/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202462876
Principal investigator 1 ABBVIE INC. $1,543.00 03/12/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202462879
Principal investigator 1 Partner Therapeutics, Inc. $10,913.60 03/12/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) No dispute reported 06/30/2026 1215516403
Principal investigator 1 Hoffmann-La Roche Limited $1,760.00 02/28/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610074
Principal investigator 1 ABBVIE INC. $4,463.00 02/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454892
Principal investigator 1 ABBVIE INC. $4,463.00 02/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454896
Principal investigator 1 ABBVIE INC. $1,543.00 02/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454927
Principal investigator 1 ABBVIE INC. $4,463.00 02/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454932
Principal investigator 1 ABBVIE INC. $1,543.00 02/27/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202454936
Principal investigator 1 Mirati Therapeutics, Inc. $30,500.00 02/21/2025 Non-covered Recipient Entity
Medstar Research Institute
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530951
Principal investigator 1 Genentech, Inc. $6,900.00 02/19/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS
1LM SCLC Tecentriq Lurbinectedin No dispute reported 06/30/2026 1211610390
Principal investigator 1 ABBVIE INC. $1,300.00 02/13/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202451697
Principal investigator 1 ABBVIE INC. $1,690.00 02/13/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202451701
Principal investigator 1 ABBVIE INC. $1,200.00 02/13/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1202451709
Principal investigator 1 Incyte Corporation $15,075.00 02/13/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474110
Principal investigator 1 Incyte Corporation $2,734.00 02/06/2025 Covered Recipient Teaching Hospital
Georgetown University Hospital
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240474114
Principal investigator 1 Hoffmann-La Roche Limited $12,300.03 02/05/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
BLU667 1101 ARROW ongoing No dispute reported 06/30/2026 1211610070
Principal investigator 1 ABBVIE INC. $1,543.00 01/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202442046
Principal investigator 1 ABBVIE INC. $1,543.00 01/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202442461
Principal investigator 1 ABBVIE INC. $1,543.00 01/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202442465
Principal investigator 1 ABBVIE INC. $1,543.00 01/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202442469
Principal investigator 1 F. Hoffmann-La Roche AG $133,495.00 01/29/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1211610336